PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21277290-8	2011	As for the 47 IotaIotaIota stage NSCLC treated with NACT, s-p53 Abs and CA12-5 remarkably decreased after NACT treatment (P=0.034 and P=0.007) and pre-NACT low s-p53 Abs correlated with high objective chemoresponse rate (P=0.016).	nact	52-56	tumor protein p53	Homo sapiens	60-63	
21277290-8	2011	As for the 47 IotaIotaIota stage NSCLC treated with NACT, s-p53 Abs and CA12-5 remarkably decreased after NACT treatment (P=0.034 and P=0.007) and pre-NACT low s-p53 Abs correlated with high objective chemoresponse rate (P=0.016).	nact	52-56	tumor protein p53	Homo sapiens	162-165	
21277290-8	2011	As for the 47 IotaIotaIota stage NSCLC treated with NACT, s-p53 Abs and CA12-5 remarkably decreased after NACT treatment (P=0.034 and P=0.007) and pre-NACT low s-p53 Abs correlated with high objective chemoresponse rate (P=0.016).	nact	106-110	tumor protein p53	Homo sapiens	60-63	
21277290-10	2011	S-p53 Abs level correlates with cancer patients" clinicalpathological parameters and can predict the chemoresponse of IotaIotaIota stage NSCLC patients during MCV-based NACT treatment.	nact	169-173	tumor protein p53	Homo sapiens	2-5	
27314292-5	2016	The relationship between the combined expression of HER2 and P53 and the efficacy of NACT was further analyzed by chi-square test.	nact	85-89	tumor protein p53	Homo sapiens	61-64	
31581548-0	2019	Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC).	nact	90-94	tumor protein p53	Homo sapiens	20-24